CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • ALXN Dashboard
  • Financials
  • Filings
  • Transcripts
  • Insider
  • Institutional
  • Shorts
  • Patents

Alexion Pharmaceuticals (ALXN)

Company Profile
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals logo

Company profile

Ticker
ALXN
Exchange
NASDAQ
Website
www.alxn.com
CEO
Ludwig Hantson
Employees
Incorporated
Delaware
Location
Massachusetts
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
Former names
ALEXION PHARMACEUTICALS INC
SEC CIK
0000899866
Corporate docs
Articles of Incorporation & Bylaws
Subsidiaries
Alexion Delaware Holding LLC • Alexion Services Latin America, Inc. • Alexion US Holdings LLC • Alexion US1 LLC • Alexion Pharma LLC • Alexion Holding LLC • Savoy Therapeutics Corp. • Wilson Therapeutics USA, Inc. • Syntimmune, Inc. • Achillion Pharmaceuticals, Inc. ...
IRS number
133648318

ALXN stock data

Latest filings (excl ownership)
View all
SC TO-T/A
Third party tender offer statement (amended)
16 Nov 22
SC TO-T
Third party tender offer statement
18 Oct 22
SC TO-C
Information about tender offer
3 Oct 22
15-12G
Securities registration termination
2 Aug 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
Transcripts
View all
ALXN
Earnings call transcript
2020 Q3
29 Oct 20
ALXN
Earnings call transcript
2020 Q2
30 Jul 20
ALXN
Earnings call transcript
2020 Q1
6 May 20
ALXN
Earnings call transcript
2019 Q4
30 Jan 20
ALXN
Earnings call transcript
2019 Q3
23 Oct 19
ALXN
Earnings call transcript
2019 Q2
24 Jul 19
ALXN
Earnings call transcript
2019 Q1
25 Apr 19
ALXN
Earnings call transcript
2018 Q4
4 Feb 19
ALXN
Earnings call transcript
2018 Q3
24 Oct 18
ALXN
Earnings call transcript
2018 Q2
26 Jul 18
Latest ownership filings
View all
SC 13G/A
BlackRock Inc.
9 Aug 21
4
CHRISTOPHER J COUGHLIN
23 Jul 21
4
ARADHANA SARIN
23 Jul 21
4
PAUL A FRIEDMAN
23 Jul 21
4
Judith A Reinsdorf
23 Jul 21
4
Deborah Dunsire
23 Jul 21
4
Tanisha Carino
23 Jul 21
4
John T Mollen
23 Jul 21
4
David R Brennan
23 Jul 21
4
Brian Goff
23 Jul 21

Financial summary

Financial statements Chart ALXN financial data
Quarter (USD) Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Institutional ownership, Q3 2022

ALXN institutional ownership history Ownership history
0.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1 1 –
Opened positions 0 0
Closed positions 0 1 EXIT
Increased positions 1 0 NEW
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 16.00 k 13.00 k +23.1%
Total shares 61.00 60.00 +1.7%
Total puts 0.00 0.00
Total calls 0.00 0.00
Total put/call ratio – – –
Largest owners Shares Value Change
Retirement 61.00 $16.00 k +1.7%
Largest transactions Shares Bought/sold Change
Retirement 61.00 +1.00 +1.7%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn